The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...
Early real-world findings show that Carvykti, a BCMA-directed CAR T-cell therapy, is demonstrating sustained remissions in ...
Pfizer announced it has entered into an exclusive global collaboration and license agreement with Chongqing Yao ...
Carvykti’s emerging Phase III data shows that a single early-line infusion can deliver durable, treatment-free remissions ...
In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met ...
Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...
For Phase III trial planning, two suggestions may have merit. Include sizeable subpopulations that payers cannot easily ...
The European pharmaceutical market, representing 20% of the global pharmaceutical market, is not a fortress to be feared but an opportunity to be seized.
Scientific advice by EMA. At different stages of your development process, you can go for scientific advice with the EMA. While this service is not free, the associated fees can vary, typically ...
When borders become bottlenecks, leadership—not luck—keeps medicines flowing to the patients that need them. The companies that adapt these new practices will find new opportunities in the changed ...
In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a head-to-head Phase III trial against Imbruvica for ...
PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of biosimilar development have been the European agency, the UK, and US FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback